Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
The combination continued to best CHOP at 5 years.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
The median duration of response was 31.6 months, and the median duration of complete response was not reached.
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
